BAM
IGMS

Blueshift Asset Management’s IGM Biosciences IGMS Stock Holding History

Blueshift Asset Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,825
Closed -$318K – 1137
2021
Q2 		$318K Buy
+3,825
New +$283K 0.02% 709

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Blueshift Asset Management's IGMS Position: Q3 2021 in Review

Blueshift Asset Management sold out of IGM Biosciences (IGMS) in Q3 2021, closing a stake of 3,825 shares — an estimated $318K sold.

Blueshift Asset Management first reported a position in IGMS in Q2 2021 and held it in 1 quarter. The position peaked at $318K in Q2 2021. 107 funds tracked by Wall St. Rank hold IGMS as of Q3 2021.

  • Blueshift Asset Management reported no remaining IGM Biosciences position as of Q3 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 3,825 IGM Biosciences shares in Q3 2021, an estimated $318K.
  • Blueshift Asset Management first reported a position in IGM Biosciences in Q2 2021 and held it in 1 quarter.
  • Blueshift Asset Management's IGM Biosciences position peaked at $318K in Q2 2021.
  • 107 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2021.

Based on Blueshift Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.